With this issue we welcome three members to the distinguished editorial advisory board that has guided Contemporary OB/GYN since its inception.
Yalda Afshar, MD, PhD; Christine Isaacs, MD; and Laura Riley, MD begin their time in lending expertise to the content in these pages and online. You can read more about each remarkable scientist here.
We hope you also will find the content in this issue rich and informative. The Society for Maternal-Fetal Medicine (SMFM) shares its Consult Series #50 on Activity Restriction in obstetric management. Editor-in-Chief Catherine Y. Spong, MD, dedicates her editorial to the topic with an endorsement to put activity restriction to bed – her pun fully intended – as research now is available to provide guidance for practitioners recommending against its routine use.
Practitioners continue to navigate health care in a pandemic, conducting much patient communication virtually. Four doctors from Yale—Linda L. Fan, MD, FACOG; Shefali R. Pathy, MD, MPH; Julia Cron, MD; and Sangini S. Sheth, MD, MPH—offer their guidance on managing the Well Woman visit via telehealth.
In the first article of a two-part series, Amanda Kallen, MD, and Sandra Ann Carson, MD, offer a thorough guide to diagnosing an infertile couple. Watch for next month’s article as well, where they provide a guide for treatment.
Ronald J. Wapner, MD, makes a case for improved carrier screening. Ideally, women of reproductive age would be offered carrier screening before conception to maximize the subsequent reproductive options for carrier couples, he says.
Please let us know what you think of this content; reader feedback is invited by emailing Senior Editor Angie DeRosa at aderosa@mjhlifesciences.com.
__
Mike Hennessy, Sr.
Chairman and Founder, MJH Life Sciences
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More